WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2004099148) SUBSTITUTED PYRIMIDINE DERIVATIVES
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2004/099148    International Application No.:    PCT/IB2004/001410
Publication Date: 18.11.2004 International Filing Date: 26.04.2004
Chapter 2 Demand Filed:    03.06.2004    
IPC:
C07D 213/72 (2006.01), C07D 239/42 (2006.01)
Applicants: PHARMACIA & UPJOHN COMPANY LLC [US/US]; 301 Henrietta Street, Kalamazoo, MI 49001 (US) (For All Designated States Except US).
CORBETT, Jeffrey, Wayne [US/US]; (US) (For US Only).
ENNIS, Michael, Dalton [US/US]; (US) (For US Only).
FRANK, Kristine, Elizabeth [US/US]; (US) (For US Only).
FU, Jian-min [US/CA]; (CA) (For US Only).
HOFFMAN, Robert, Louis [US/US]; (US) (For US Only).
VERHOEST, Patrick, Robert [US/US]; (US) (For US Only)
Inventors: CORBETT, Jeffrey, Wayne; (US).
ENNIS, Michael, Dalton; (US).
FRANK, Kristine, Elizabeth; (US).
FU, Jian-min; (CA).
HOFFMAN, Robert, Louis; (US).
VERHOEST, Patrick, Robert; (US)
Agent: LUMB, J., Trevor; c/o Jackie Lawrence, Pfizer Inc., Mailstop 8260-1615, Eastern Point Road, Groton, CT 06340 (US)
Priority Data:
60/469,487 09.05.2003 US
Title (EN) SUBSTITUTED PYRIMIDINE DERIVATIVES
(FR) DERIVES PYRIMIDIQUES SUBSTITUES
Abstract: front page image
(EN)This invention relates to compounds of Formula I, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a prodrug thereof, or a pharmaceutically acceptable salt of a prodrug thereof. The compounds interact with CRF1 receptors, including human CRF1 receptors. This invention also relates to methods of using the compounds of the invention to treat a disorder or condition, the treatment of which can be effected or facilitated by antagonizing a CRF receptor, such as CNS disorders or diseases, particularly anxiety-related disorders such as anxiety, and mood disorders such as major depression.
(FR)L'invention concerne des composés de formule (I), leur stéréoisomère, leur sel pharmaceutiquement acceptable, leur promédicament, ou bien un sel pharmaceutiquement acceptable de leur promédicament. Ces composés ont une interaction avec les récepteurs du CRF1, en particulier les récepteurs du CRF1 humain. La présente invention concerne également des méthodes pour utiliser ces composés en vue de traiter un trouble ou un état pathologique dont le traitement peut être effectué ou facilité par l'opposition aux effets d'un récepteur du CRF, par exemple des troubles ou des maladies du système nerveux central, notamment des troubles liés à l'anxiété, tels que l'angoisse, et des troubles de l'humeur, tels que la dépression majeure.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)